Clinical trial
A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected…
NCT00113412 · Samaritan Pharmaceuticals, Inc, Industry · Unknown status
Key facts
| NCT number | NCT00113412 |
|---|---|
| Title | A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected Patients |
| Official title | A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study Of Orally Administered SP01A As Monotherapy Treatment Of HIV-Infected Patients |
| Lead sponsor | Samaritan Pharmaceuticals, Inc, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | SP01A |
| Enrollment | 32 |
| Start date | May 1, 2005 |
| First posted | Jun 8, 2005 |
| Last update posted | Mar 22, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: